1
|
Ferraro F, Sonnleitner L, Neut C, Mahieux S, Verin J, Siepmann J, Siepmann F. Colon targeting in rats, dogs and IBD patients with species-independent film coatings. Int J Pharm X 2024; 7:100233. [PMID: 38379554 PMCID: PMC10876578 DOI: 10.1016/j.ijpx.2024.100233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 02/06/2024] [Accepted: 02/06/2024] [Indexed: 02/22/2024] Open
Abstract
Polysaccharides were identified, which allow for colon targeting in human Inflammatory Bowel Disease (IBD) patients, as well as in rats and dogs (which are frequently used as animals in preclinical studies). The polysaccharides are degraded by colonic enzymes (secreted by bacteria), triggering the onset of drug release at the target site. It has to be pointed out that the microbiota in rats, dogs and humans substantially differ. Thus, the performance of this type of colon targeting system observed in animals might not be predictive for patients. The aim of this study was to limit this risk. Different polysaccharides were exposed to culture medium inoculated with fecal samples from IBD patients, healthy dogs and "IBD rats" (in which colonic inflammation was induced). Dynamic changes in the pH of the culture medium were used as an indicator for the proliferation of the bacteria and, thus, the potential of the polysaccharides to serve as their substrate. Fundamental differences were observed with respect to the extent of the pH variations as well as their species-dependency. The most promising polysaccharides were used to prepare polymeric film coatings surrounding 5-aminosaliciylic acid (5-ASA)-loaded starter cores. To limit premature polysaccharide dissolution/swelling in the upper gastro intestinal tract, ethylcellulose was also included in the film coatings. Drug release was monitored upon exposure to culture medium inoculated with fecal samples from IBD patients, healthy dogs and "IBD rats". For reasons of comparison, also 5-ASA release in pure culture medium was measured. Most film coatings showed highly species-dependent drug release kinetics or limited colon targeting capacity. Interestingly, extracts from aloe vera and reishi (a mushroom) showed a promising potential for colon targeting in all species.
Collapse
Affiliation(s)
- F. Ferraro
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | | | - C. Neut
- Univ. Lille, Inserm, CHU Lille, U1286, F-59000 Lille, France
| | - S. Mahieux
- Univ. Lille, Inserm, CHU Lille, U1286, F-59000 Lille, France
| | - J. Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J. Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F. Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| |
Collapse
|
2
|
Lefol L, Bawuah P, Zeitler J, Verin J, Danede F, Willart J, Siepmann F, Siepmann J. Drug release from PLGA microparticles can be slowed down by a surrounding hydrogel. Int J Pharm X 2023; 6:100220. [PMID: 38146325 PMCID: PMC10749250 DOI: 10.1016/j.ijpx.2023.100220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/23/2023] [Accepted: 11/25/2023] [Indexed: 12/27/2023] Open
Abstract
This study aimed to evaluate and better understand the potential impact that a layer of surrounding hydrogel (mimicking living tissue) can have on the drug release from PLGA microparticles. Ibuprofen-loaded microparticles were prepared with an emulsion solvent extraction/evaporation method. The drug loading was about 48%. The surface of the microparticles appeared initially smooth and non-porous. In contrast, the internal microstructure of the particles exhibited a continuous network of tiny pores. Ibuprofen release from single microparticles was measured into agarose gels and well-agitated phosphate buffer pH 7.4. Optical microscopy, scanning electron microscopy, differential scanning calorimetry, X-ray powder diffraction, and X-ray μCT imaging were used to characterize the microparticles before and after exposure to the release media. Importantly, ibuprofen release was much slower in the presence of a surrounding agarose gel, e.g., the complete release took two weeks vs. a few days in well agitated phosphate buffer. This can probably be attributed to the fact that the hydrogel sterically hinders substantial system swelling and, thus, slows down the related increase in drug mobility. In addition, in this particular case, the convective flow in agitated bulk fluid likely damages the thin PLGA layer at the microparticles' surface, giving the outer aqueous phase more rapid access to the inner continuous pore network: Upon contact with water, the drug dissolves and rapidly diffuses out through a continuous network of water-filled channels. Without direct surface access, most of the drug "has to wait" for the onset of substantial system swelling to be released.
Collapse
Affiliation(s)
- L.A. Lefol
- Univ. Lille, Inserm, CHU Lille, U1008, Lille F-59000, France
| | - P. Bawuah
- Univ. Cambridge, Department of Chemical Engineering and Biotechnology, Cambridge CB3 0AS, UK
| | - J.A. Zeitler
- Univ. Cambridge, Department of Chemical Engineering and Biotechnology, Cambridge CB3 0AS, UK
| | - J. Verin
- Univ. Lille, Inserm, CHU Lille, U1008, Lille F-59000, France
| | - F. Danede
- Univ. Lille, USTL UMET UMR CNRS 8207, Villeneuve d'Ascq F-59650, France
| | - J.F. Willart
- Univ. Lille, USTL UMET UMR CNRS 8207, Villeneuve d'Ascq F-59650, France
| | - F. Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, Lille F-59000, France
| | - J. Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, Lille F-59000, France
| |
Collapse
|
3
|
Bassand C, Siepmann F, Benabed L, Verin J, Freitag J, Charlon S, Soulestin J, Siepmann J. 3D printed PLGA implants: How the filling density affects drug release. J Control Release 2023; 363:1-11. [PMID: 37714435 DOI: 10.1016/j.jconrel.2023.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 07/22/2023] [Accepted: 09/10/2023] [Indexed: 09/17/2023]
Abstract
Different types of ibuprofen-loaded, poly (D,L lactic-co-glycolic acid) (PLGA)-based implants were prepared by 3D printing (Droplet Deposition Modeling). The theoretical filling density of the mesh-shaped implants was varied from 10 to 100%. Drug release was measured in agarose gels and in well agitated phosphate buffer pH 7.4. The key properties of the implants (and dynamic changes thereof upon exposure to the release media) were monitored using gravimetric measurements, optical microscopy, Differential Scanning Calorimetry, Gel Permeation Chromatography, and Scanning Electron Microscopy. Interestingly, drug release was similar for implants with 10 and 30% filling density, irrespective of the experimental set-up. In contrast, implants with 100% filling density showed slower release kinetics, and the shape of the release curve was altered in agarose gels. These observations could be explained by the existence (or absence) of a continuous aqueous phase between the polymeric filaments and the "orchestrating role" of substantial system swelling for the control of drug release. At lower filling densities, it is sufficient for the drug to be released from a single filament. In contrast, at high filling densities, the ensemble of filaments acts as a much larger (more or less homogeneous) polymeric matrix, and the average diffusion pathway to be overcome by the drug is much longer. Agarose gel (mimicking living tissue) hinders substantial PLGA swelling and delays the onset of the final rapid drug release phase. This improved mechanistic understanding of the control of drug release from PLGA-based 3D printed implants can help to facilitate the optimization of this type of advanced drug delivery systems.
Collapse
Affiliation(s)
- C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - L Benabed
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Freitag
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - S Charlon
- IMT Lille Douai, Dept Polymers & Composites Technol & Mech Engn, F-59500 Douai, France
| | - J Soulestin
- IMT Lille Douai, Dept Polymers & Composites Technol & Mech Engn, F-59500 Douai, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
4
|
Bassand C, Benabed L, Charlon S, Verin J, Freitag J, Siepmann F, Soulestin J, Siepmann J. 3D printed PLGA implants: APF DDM vs. FDM. J Control Release 2023; 353:864-874. [PMID: 36464064 DOI: 10.1016/j.jconrel.2022.11.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 11/21/2022] [Accepted: 11/29/2022] [Indexed: 12/23/2022]
Abstract
3D Printing offers a considerable potential for personalized medicines. This is especially true for customized biodegradable implants, matching the specific needs of each patient. Poly(lactic-co-glycolic acid) (PLGA) is frequently used as matrix former in biodegradable implants. However, yet relatively little is known on the technologies, which can be used for the 3D printing of PLGA implants. The aim of this study was to compare: (i) Arburg Plastic Freeforming Droplet Deposition Modeling (APF DDM), and (ii) Fused Deposition Modeling (FDM) to print mesh-shaped, ibuprofen-loaded PLGA implants. During APF DDM, individual drug-polymer droplets are deposited, fusing together to form filaments, which build up the implants. During FDM, continuous drug-polymer filaments are deposited to form the meshes. The implants were thoroughly characterized before and after exposure to phosphate buffer pH 7.4 using optical and scanning electron microscopy, GPC, DSC, drug release measurements and monitoring dynamic changes in the systems' dry & wet mass and pH of the bulk fluid. Interestingly, the mesh structures were significantly different, although the device design (composition & theoretical geometry) were the same. This could be explained by the fact that the deposition of individual droplets during APF DDM led to curved and rather thick filaments, resulting in a much lower mesh porosity. In contrast, FDM printing generated straight and thinner filaments: The open spaces between them were much larger and allowed convective mass transport during drug release. Consequently, most of the drug was already released after 4 d, when substantial PLGA set on. In the case of APF DDM printed implants, most of the drug was still entrapped at that time point and substantial polymer swelling transformed the meshes into more or less continuous PLGA gels. Hence, the diffusion pathways became much longer and ibuprofen release was controlled over 2 weeks.
Collapse
Affiliation(s)
- C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - L Benabed
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - S Charlon
- IMT Lille Douai, École Nationale Supérieure Mines-Télécom Lille Douai, Materials & Processes Center, Cité Scientifique, Villeneuve d'Ascq Cedex, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Freitag
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Soulestin
- IMT Lille Douai, École Nationale Supérieure Mines-Télécom Lille Douai, Materials & Processes Center, Cité Scientifique, Villeneuve d'Ascq Cedex, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
5
|
Bassand C, Benabed L, Freitag J, Verin J, Siepmann F, Siepmann J. How bulk fluid renewal can affect in vitro drug release from PLGA implants: Importance of the experimental set-up. Int J Pharm X 2022; 4:100131. [PMID: 36189458 PMCID: PMC9519472 DOI: 10.1016/j.ijpx.2022.100131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 08/30/2022] [Accepted: 09/16/2022] [Indexed: 11/08/2022] Open
Abstract
The aim of this study was to better understand the potential impact of partial vs. complete renewal of the bulk fluid during drug release measurements from poly (lactic-co-glycolic acid) (PLGA)-based implants. A “standard experimental set-up”, in which the implants were directly exposed to well agitated phosphate buffer pH 7.4 was used, as well as set-ups, in which the implants were embedded within agarose hydrogels (mimicking living tissue). The gels were exposed to well agitated phosphate buffer pH 7.4. Ibuprofen-loaded implants were prepared by hot melt extrusion. The systems were thoroughly characterized before and during drug release by optical and scanning electron microscopy, gravimetric analysis, pH and solubility measurements as well as gel permeation chromatography. The bulk fluid was either completely or partially replaced by fresh medium at each sampling time point. In all cases, sink conditions were provided in the agitated bulk fluids throughout the experiments. Interestingly, the agarose set-ups did not show any noteworthy impact of the bulk fluid sampling volume on the observed drug release patterns, whereas complete fluid renewal in the “standard set-up” led to accelerated drug release. This could be explained by the considerable fragility of the implants once substantial polymer swelling set on, transforming them into PLGA gels: Complete fluid renewal caused partial disintegration and damage of the highly swollen systems, decreasing the lengths of the diffusion pathways for the drug. The mechanical stress is very much reduced at low sampling volumes, or if the implants are embedded within agarose gels. Thus, great care must be taken when defining the conditions for in vitro drug release measurements from PLGA-based implants: Once substantial system swelling sets on, the devices become highly fragile.
Collapse
|
6
|
Rongthong T, Qnouch A, Gehrke MM, Danede F, Willart J, Oliveira P, Paccou L, Tourrel G, Stahl P, Verin J, Toulemonde P, Vincent C, Siepmann F, Siepmann J. Long term behavior of dexamethasone-loaded cochlear implants: In vitro & in vivo. Int J Pharm X 2022; 4:100141. [DOI: 10.1016/j.ijpx.2022.100141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/17/2022] [Accepted: 11/19/2022] [Indexed: 11/23/2022] Open
|
7
|
Bassand C, Freitag J, Benabed L, Verin J, Siepmann F, Siepmann J. PLGA implants for controlled drug release: Impact of the diameter. Eur J Pharm Biopharm 2022; 177:50-60. [PMID: 35659920 DOI: 10.1016/j.ejpb.2022.05.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 05/24/2022] [Accepted: 05/27/2022] [Indexed: 11/17/2022]
Abstract
The aim of this study was to better understand the importance of the diameter of poly(lactic-co-glycolic acid) (PLGA)-based implants on system performance, in particular the control of drug release. Different types of ibuprofen-loaded implants were prepared by hot melt extrusion using a Leistritz Nano 16 twin-screw extruder. Drug release was measured in well agitated phosphate buffer pH7.4 bulk fluid and in agarose gels in Eppendorf tubes or transwell plates. Dynamic changes in the implants' dry & wet mass, volume, polymer molecular weight as well as inner & outer morphology were monitored using gravimetric analysis, optical macroscopy, gel permeation chromatography and scanning electron microscopy. The physical states of the drug and polymer were determined by DSC. Also pH changes in the release medium were investigated. Irrespective of the type of experimental set-up, the resulting absolute and relative drug release rates decreased with increasing implant diameter (0.7 to 2.8 mm). Bi-phasic drug release was observed in all cases from the monolithic solutions (ibuprofen was dissolved in the polymer): A zero order release phase was followed by a final, rapid drug release phase (accounting for 80-90% of the total drug dose). The decrease in the relative drug release rate with increasing system diameter can be explained by the increase in the diffusion pathway lengths to be overcome. Interestingly, also the onset of the final rapid drug release phase was delayed with increasing implant diameter. This can probably be attributed to the higher mechanical stability of thicker devices, offering more resistance to substantial entire system swelling.
Collapse
Affiliation(s)
- C Bassand
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Freitag
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - L Benabed
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
8
|
Bassand C, Benabed L, Verin J, Danede F, Lefol L, Willart J, Siepmann F, Siepmann J. Hot melt extruded PLGA implants loaded with ibuprofen: How heat exposure alters the physical drug state. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103432] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
9
|
Qnouch A, Solarczyk V, Verin J, Tourrel G, Stahl P, Danede F, Willart JF, Lemesre PE, Vincent C, Siepmann J, Siepmann F. Dexamethasone-loaded cochlear implants: How to provide a desired "burst release". Int J Pharm X 2021; 3:100088. [PMID: 34553137 PMCID: PMC8441626 DOI: 10.1016/j.ijpx.2021.100088] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/23/2021] [Revised: 06/03/2021] [Accepted: 06/06/2021] [Indexed: 12/20/2022]
Abstract
Cochlear implants containing iridium platinum electrodes are used to transmit electrical signals into the inner ear of patients suffering from severe or profound deafness without valuable benefit from conventional hearing aids. However, their placement is invasive and can cause trauma as well as local inflammation, harming remaining hair cells or other inner ear cells. As foreign bodies, the implants also induce fibrosis, resulting in a less efficient conduction of the electrical signals and, thus, potentially decreased system performance. To overcome these obstacles, dexamethasone has recently been embedded in this type of implants: into the silicone matrices separating the metal electrodes (to avoid short circuits). It has been shown that the resulting drug release can be controlled over several years. Importantly, the dexamethasone does not only act against the immediate consequences of trauma, inflammation and fibrosis, it can also be expected to be beneficial for remaining hair cells in the long term. However, the reported amounts of drug released at “early” time points (during the first days/weeks) are relatively low and the in vivo efficacy in animal models was reported to be non-optimal. The aim of this study was to increase the initial “burst release” from the implants, adding a freely water-soluble salt of a phosphate ester of dexamethasone. The idea was to facilitate water penetration into the highly hydrophobic system and, thus, to promote drug dissolution and diffusion. This approach was efficient: Adding up to 10% dexamethasone sodium phosphate to the silicone matrices substantially increased the resulting drug release rate at early time points. This can be expected to improve drug action and implant functionality. But at elevated dexamethasone sodium phosphate loadings device swelling became important. Since the cochlea is a tiny and sensitive organ, a potential increase in implant dimensions over time must be limited. Hence, a balance has to be found between drug release and implant swelling.
Collapse
Affiliation(s)
- A Qnouch
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - V Solarczyk
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - G Tourrel
- Oticon Medical, R&D, 06224 Vallauris, France
| | - P Stahl
- Oticon Medical, R&D, 06224 Vallauris, France
| | - F Danede
- Univ. Lille, UMR CNRS 8207, UMET, F-59655 Villeneuve d'Ascq, France
| | - J F Willart
- Univ. Lille, UMR CNRS 8207, UMET, F-59655 Villeneuve d'Ascq, France
| | - P E Lemesre
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - C Vincent
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| |
Collapse
|
10
|
Gehrke M, Verin J, Gnansia D, Tourrel G, Risoud M, Vincent C, Siepmann F, Siepmann J. Hybrid Ear Cubes for local controlled dexamethasone delivery to the inner ear. Eur J Pharm Sci 2018; 126:23-32. [PMID: 29723597 DOI: 10.1016/j.ejps.2018.04.045] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Revised: 04/18/2018] [Accepted: 04/29/2018] [Indexed: 01/13/2023]
Abstract
A new type of miniaturized implants for local controlled drug delivery to the inner ear is proposed: Hybrid Ear Cubes. They are composed of two main parts: (i) a cylinder, which is placed into a tiny hole (<0.4 mm) drilled into (or close to) the oval (or round) window, and (ii) a cuboid, which is placed into the middle ear. The drug is released at a pre-programmed rate into the perilymph: (i) via the cylindrical part of the implant, which is in direct contact with this liquid, and (ii) via diffusion from the cuboid through the oval/round window. Importantly, the cylindrical part assures a reliable fixation of the drug delivery system at the site of administration. Furthermore, the cuboid provides a relatively "large" drug reservoir, without expulsing perilymph from the cochlea. The required surgery is minimized compared to the placement of an intracochlear implant. In contrast to previously proposed Ear Cubes, which are mono-block systems, Hybrid Ear Cubes consist of two halves, which can: (i) be loaded with different drugs, (ii) be loaded with the same drug at different concentrations, and/or (iii) be based on two different matrix formers. This offers a substantially increased formulation flexibility. Different types of silicone-based Hybrid Ear Cubes were prepared, loaded with 10% dexamethasone in one half and 0-60% dexamethasone in the other half. Importantly, tiny drug crystals were homogeneously distributed throughout the respective implant halves. The observed drug release rates were very low (e.g., <0.5% after 2 months), which can be attributed to the type of drug and silicone as well as to the very small surface area exposed to the release medium. Importantly, no noteworthy implant swelling was observed.
Collapse
Affiliation(s)
- M Gehrke
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Verin
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - D Gnansia
- Oticon Medical/Neurelec, R&D, 2720 Chemin Saint-Bernard, F-06224 Vallauris, France
| | - G Tourrel
- Oticon Medical/Neurelec, R&D, 2720 Chemin Saint-Bernard, F-06224 Vallauris, France
| | - M Risoud
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - C Vincent
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - F Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
| | - J Siepmann
- Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
| |
Collapse
|
11
|
Gasmi H, Siepmann F, Hamoudi M, Danede F, Verin J, Willart JF, Siepmann J. Towards a better understanding of the different release phases from PLGA microparticles: Dexamethasone-loaded systems. Int J Pharm 2016; 514:189-199. [DOI: 10.1016/j.ijpharm.2016.08.032] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Revised: 08/03/2016] [Accepted: 08/15/2016] [Indexed: 02/03/2023]
|